📰 Modified Observer News
Modified Observer News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Modified Observer. Real-time updates on events, politics, business and more.
September 20, 2023
Seelos Therapeutics, Inc. announced top line data demonstrating clinically meaningful treatment effects across multiple endpoints and a well-tolerated safety profile from the double-blind,...
January 6, 2023
Investegate announcements from atai Life Sciences, atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
January 6, 2023
NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ("atai" or "the Company"), a clinical-stage biopharmaceutical company focused on mental health, announced that,
January 6, 2023
Atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant DepressionNEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental h...
November 10, 2022
Investegate announcements from atai Life Sciences, atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update
October 25, 2022
Completed enrollment of Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled clinical trial of PCN-101 (R-ketamine).Last patient...
October 25, 2022
Investegate announcements from atai Life Sciences, atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
October 25, 2022
Completed enrollment of Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled clinical trial of PCN-101 (R-ketamine).Last patient expected to be dosed this week, with the total number